Solugen and Sasol have entered into a strategic partnership. Photo via Getty Images

A Houston company that's creating cleaner chemicals with little to no impact on the environment has scored a partnership with a major chemicals producer.

Solugen and Sasol Chemicals, a business unit of Saslo Ltd., revealed that they are working together to explore commercialization of sustainably-made home and personal care products.

“This agreement is an example of our approach of partnering to find innovative solutions for our customers,” Jonathan Ward, senior manager of Strategy and Sustainable Growth for Sasol’s Essential Care Chemicals business division, says in a news release. “Our focus is delivering high-performing products with lower carbon footprints at competitive prices, and we are eager to see how Solugen’s products might help us do that.”

Founded in 2016 by Sean Hunt and Gaurab Chakrabarti, Solugen's carbon-negative molecule factory, named the Bioforge, uses a chemienzymatic process in converting plant-sourced substances into essential materials that can be used instead of fossil fuels. The manufacturing process is carbon neutral, and Solugen has raised over $600 million from investors that believe in the technology's potential.

"We are thrilled to partner with Sasol Chemicals, one of the world’s largest producers of surfactants, to drive positive impact in the home and personal care market,” Chakrabarti, CEO of Solugen, says in the release. “Sasol’s commitment to sustainability makes it an ideal partner for Solugen. We look forward to leveraging our combined strengths in technology, production, and market development to meet increasing consumer demand for our high-performance, bio-based solutions.”

Chakrabarti shared some of the secrets to Solugen's success and early partnerships at a SXSW panel earlier this year. The company was also recently named a finalist in the 2023 Houston Innovation Awards.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”